Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). - Wikidata - awgldk - TriplyDB

Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).

Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).

http://www.wikidata.org/entity/Q35607330

about

Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence Incretin-Based Therapy for Prevention of Diabetic Vascular Complications Dipeptidyl peptidase-4 and kidney fibrosis in diabetes Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?Dipeptidyl Peptidase-4 Regulation of SDF-1/CXCR4 Axis: Implications for Cardiovascular Disease The Role of Dipeptidyl Peptidase - 4 Inhibitors in Diabetic Kidney Disease Unraveling oxyntomodulin, GLP1's enigmatic brother Dipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protection Alogliptin benzoate for management of type 2 diabetes Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction Maternal high-fat diet prevents developmental programming by early-life stress Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway.Treatment of diabetic kidney disease: current and future targets.High glucose aggravates the detrimental effects of pancreatic stellate cells on Beta-cell function Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney.Effects of a DPP4 inhibitor on cisplatin-induced acute kidney injury: study protocol for a randomized controlled trial.Linagliptin Limits High Glucose Induced Conversion of Latent to Active TGFß through Interaction with CIM6PR and Limits Renal Tubulointerstitial Fibronectin.The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes Hepatoprotective effect of sitagliptin against methotrexate induced liver toxicity DPP-4 inhibition improves early mortality, β cell function, and adipose tissue inflammation in db/db mice fed a diet containing sucrose and linoleic acid.Angiotensin II Stimulation of DPP4 Activity Regulates Megalin in the Proximal Tubules Preventive effects of Morus alba L. anthocyanins on diabetes in Zucker diabetic fatty rats.Microvascular Outcomes in Patients with Type 2 Diabetes Treated with Vildagliptin vs. Sulfonylurea: A Retrospective Study Using German Electronic Medical Records.Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction.Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety.The effect of bariatric surgery on renal function and disease: a focus on outcomes and inflammation.Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner.The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.Diabetes, hypertension, and chronic kidney disease progression: role of DPP4.Novel avenues for treating diabetic nephropathy: new investigational drugs.Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes.The dipeptidyl peptidase-4 inhibitor sitagliptin protects against dyslipidemia-related kidney injury in Apolipoprotein E knockout mice

P2860

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

P2860

Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).

http://www.wikidata.org/entity/Q35607330

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Diabetic nephropathy ameliorat ...... s (Zucker diabetic fatty rat).

@ast

Diabetic nephropathy ameliorat ...... s (Zucker diabetic fatty rat).

@en

type

label

Diabetic nephropathy ameliorat ...... s (Zucker diabetic fatty rat).

@ast

Diabetic nephropathy ameliorat ...... s (Zucker diabetic fatty rat).

@en

prefLabel

Diabetic nephropathy ameliorat ...... s (Zucker diabetic fatty rat).

@ast

Diabetic nephropathy ameliorat ...... s (Zucker diabetic fatty rat).

@en

P1433

Q35607330-639E670B-F435-4DCA-B09A-088C7C7A241B

P1476

Q35607330-0D9B153A-9ABA-42EA-968D-49C707593B39

P2093

Q35607330-360E5C8F-33A2-4CBC-9E40-6744C090E9CA

Q35607330-C71205F8-057F-4C56-BCFD-06AC4C49A337

Q35607330-F3005907-A8CA-4221-AB6E-0B072E8E77E7

P2860

Q35607330-004AF51F-B654-465B-8DC4-FFF684D0F33B

Q35607330-02DBA782-F3C4-459C-9958-D8259EA47C20

Q35607330-0304666E-E1F0-4243-8352-7BB7432D79D5

Q35607330-11D4B8EC-C0E0-465C-AF1C-405A05273886

Q35607330-1842E9C6-4B88-45B8-85C0-5CAD50F20EE9

Q35607330-1DB9826C-6B1D-4D57-A6D2-DC6F5FD1A44E

Q35607330-229B64D1-4E44-48F0-BD4E-8E0D50E31EAB

Q35607330-27A3CF67-37FB-4BAA-A99C-E7AF71F46015

Q35607330-3050B499-A839-46CD-9A4C-0A2A4F06A79B

Q35607330-38AD8CA5-CB86-4801-BEE2-D51614B02D9A

P304

Q35607330-3C713138-2499-42CA-8091-7211560D6525

P31

Q35607330-763024CE-2131-4EA5-836C-EB15A11C340E

P356

Q35607330-1638B328-2890-4611-8D04-9BA0B1295333

P478

Q35607330-4FA52CE9-EA98-46DD-99FB-3E04495EF2DD

P50

Q35607330-13CD93FC-E04F-4470-968B-99407F3FFD2C

Q35607330-27A58742-859F-47E2-9EB4-18F5B8A98B2F

Q35607330-288E1ACC-1382-41E8-9DD5-6250718020CB

Q35607330-604A5D14-F7B2-413C-A3D8-CABB64DF5EE5

Q35607330-B5BB19D8-F2C2-464A-B85D-609924F58A94

Q35607330-D1A25855-7AB6-4214-8BC1-A71DCAAC68F8

P577

Q35607330-6DCC06CE-3BC3-4DF7-A627-ECE00DFF6E2E

P5875

Q35607330-59D015EC-49D2-466B-B757-D50D59B45E47

P698

Q35607330-83551519-FB30-4BA6-886B-A7C7B5D35EC0

P921

Q35607330-6005186C-F3C6-45B8-8E48-9E695D6566E1

P932

Q35607330-3FE62B67-DFE9-4BB5-AE75-B38EEF6F52FC

P356

P1433

Experimental Diabetes Research

P1476

Diabetic nephropathy ameliorat ...... es (Zucker diabetic fatty rat)

@en

P2093

Cristina Mega

http://www.w3.org/2001/XMLSchema#string

Edite Teixeira de Lemos

http://www.w3.org/2001/XMLSchema#string

Filipa Mascarenhas-Melo

http://www.w3.org/2001/XMLSchema#string

P2860

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

Use and abuse of HOMA modeling

Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study.

Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B.

Progression of diabetic nephropathy. Insights from cell culture studies and animal models.

Rodent models of nephropathy associated with type II diabetes.

Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)

Obesity-related glomerulopathy: an emerging epidemic.

Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitus

The biology of incretin hormones.

P304

162092

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2011/162092

http://www.w3.org/2001/XMLSchema#string

P478

2011

http://www.w3.org/2001/XMLSchema#string

P50

Frederico Teixeira

Edite Teixeira-Lemos

P577

2011-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51954195

http://www.w3.org/2001/XMLSchema#string

P698

22203828

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3235777

http://www.w3.org/2001/XMLSchema#string